Larkspur Biosciences

About Larkspur Biosciences

Larkspur Bioscience is dedicated to destroying tumors by targeting cancer cell fitness. They develop small molecules to overcome limitations in cancer treatment, decreasing cancer cell fitness and sensitizing them to intrinsic and immune-driven mechanisms of killing.

Products & Services

Small Molecules for Cancer Treatment:Therapies that target enzymes controlling cancer cell state and fitness, making cancer cells susceptible to intrinsic and immune-mediated killing.

Specialties

Cancer Cell Fitness Targeting Small Molecule Development Immune-Mediated Cancer Therapies

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Seed and Series A T: - FT: Seed and Series A	A: 35500000 MR: - FA: 35.5 million FAN: 35500000	D: 2023-05-23 FD: 2023-05-23	6 investors

Seed and Series A Latest

2023-05-23

$35.5M

6 investors (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

C

Catherine Sabatos-Peyton

Chief Executive Officer

K

Krista Goodman

Chief Scientific Officer

L

Lewis C. Cantley

Professor of Medicine and Professor of Cell Biology

N

Nathanael Gray

Krishnan-Shah Professor of Chemical and Systems Biology at Stanford

V

Vijay K. Kuchroo

Samuel L. Wasserstrom Professor of Neurology at Harvard Medical School and Senior Scientist at Brigham and Women's Hospital

A

Antoni Ribas

Scientific Advisor

View 11 more team members with Pro

Unlock Full Team Directory

Recent News